Recent reversals by the U.S. Food and Drug Administration regarding acceptance of externally controlled studies have created uncertainty among biopharma firms developing treatments for rare diseases. While some companies saw initial encouragement from regulators using real-world evidence or historical data as comparators in pivotal trials, shifting requirements have led others back into more traditional study designs.
